search
Back to results

Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)

Primary Purpose

Papilloma

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Cidofovir
Sponsored by
National Institute of Allergy and Infectious Diseases (NIAID)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Papilloma

Eligibility Criteria

2 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Your child may be eligible for this study if he/she: Has active laryngeal papillomatosis (warts in the throat) that requires 8 or more surgeries per year. Developed this infection before the age of 16. Is between the ages of 2 and 17 years with consent of parent or guardian. Exclusion Criteria: Your child will not be eligible for this study if he/she: Has a history of a prior malignancy (cancer), kidney disease, or immune system deficiency. Is HIV-positive. Is allergic to probenecid. Has received radiation therapy to the throat area or has received certain medications. Is pregnant or breast-feeding.

Sites / Locations

  • NIAID/DMID/CASG Central Unit

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
January 17, 2000
Last Updated
August 26, 2010
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT00001126
Brief Title
Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)
Official Title
A Phase I/II Evaluation of Cidofovir Therapy For Recurrent Laryngeal Papillomatosis in Children
Study Type
Interventional

2. Study Status

Record Verification Date
November 2005
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2005 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to see what dose of the drug cidofovir is safe to treat laryngeal papillomatosis (warts in the throat which occur over and over) in children. Laryngeal papillomatosis is caused by infection with a virus called human papillomavirus (HPV). At present, there is no approved drug to treat this infection. However, cidofovir is a drug effective against several viruses. Cidofovir may be able to attack the HPV virus. This study tests the safety of giving this drug to children.
Detailed Description
Your child will be assigned randomly (like tossing a coin) to receive either cidofovir or placebo (an inactive substance). Neither you nor your doctor will know which your child is receiving. Your child will undergo a total of 6 bronchoscopic procedures, which involves placing a tube down your child's throat so that the warts can be seen and treated. The warts will be removed by laser or other procedures and the study drug injected. Study drug will be injected at the sites of all newly removed warts and warts which were removed during earlier study visits. This procedure will be performed every other week. Blood and urine tests will also be performed at this time. Your child will be under general anesthesia during each procedure and will be in the surgery unit for about 6 to 8 hours. Your child will also have to be seen by the doctor 2 days after the procedure. Your child will be followed for a total of 5 years to make sure he/she develops normally and to monitor any side effects of cidofovir. Follow-up visits will take place at Months 3, 6, and then once every 6 months through Year 5. If necessary, laser or other procedures will be performed at these visits to remove any warts.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Papilloma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Masking
Double
Enrollment
36 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Cidofovir

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Your child may be eligible for this study if he/she: Has active laryngeal papillomatosis (warts in the throat) that requires 8 or more surgeries per year. Developed this infection before the age of 16. Is between the ages of 2 and 17 years with consent of parent or guardian. Exclusion Criteria: Your child will not be eligible for this study if he/she: Has a history of a prior malignancy (cancer), kidney disease, or immune system deficiency. Is HIV-positive. Is allergic to probenecid. Has received radiation therapy to the throat area or has received certain medications. Is pregnant or breast-feeding.
Facility Information:
Facility Name
NIAID/DMID/CASG Central Unit
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)

We'll reach out to this number within 24 hrs